Antibiotic resistance of Helicobacter pylori in pediatric patients -- 10 years' experience

Iva Hojsak1, Tea Kos, Jelena Dumančić

  • 1Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, University of Zagreb Medical School, Klaićeva 16, Zagreb, Croatia. ivahojsak@gmail.com

Insights

Antibiotic resistance in pediatric Helicobacter pylori infections is significant, particularly to azithromycin and clarithromycin. Susceptibility testing before treatment is crucial for effective eradication therapy in children.

Area of Science:

  • Pediatric Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Helicobacter pylori (H. pylori) infection is common in children.
  • Antibiotic resistance is a growing concern for H. pylori eradication.
  • Understanding resistance patterns is vital for effective treatment strategies.

Purpose of the Study:

  • To analyze the trends in antibiotic resistance of H. pylori in children over a decade.
  • To determine the prevalence of resistance to key antibiotics used for H. pylori eradication.
  • To identify risk factors associated with H. pylori infection in pediatric patients.

Main Methods:

  • Retrospective analysis of pediatric patients undergoing upper endoscopy (2001-2010).
  • Inclusion of data from 3,008 children, with 382 H. pylori positive cases identified via biopsy.
  • Assessment of antibiotic susceptibility for H. pylori strains from treatment-naïve and treatment-failure groups.

Main Results:

  • H. pylori infection prevalence remained stable over the 10-year period.
  • Higher rates of infection were observed in older children and those with antral nodularity or duodenal ulcers.
  • Resistance rates in treatment-naïve patients were 22.4%, with high prevalence for azithromycin (17.9%) and clarithromycin (11.9%).
  • In eradication failure cases, 9/11 children had resistant strains, predominantly to metronidazole.

Conclusions:

  • Pediatric H. pylori infections exhibit significant antibiotic resistance, necessitating susceptibility testing.
  • Current guidelines recommending susceptibility testing before eradication therapy are strongly supported.
  • An amoxicillin-metronidazole-based regimen is suggested as a potential first-line therapy for this population.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...